NASDAQ:CCXI - ChemoCentryx Stock Price, Forecast & News

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

ChemoCentryx Inc (NASDAQ:CCXI) posted its quarterly earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.06. The biopharmaceutical company had revenue of $10.58 million for the quarter, compared to analyst estimates of $7.83 million. ChemoCentryx had a negative net margin of 143.30% and a negative return on equity of 88.76%. View ChemoCentryx's Earnings History.

ChemoCentryx is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for ChemoCentryx.

6 brokers have issued 1-year price objectives for ChemoCentryx's stock. Their forecasts range from $22.00 to $60.00. On average, they expect ChemoCentryx's stock price to reach $44.67 in the next twelve months. This suggests that the stock has a possible downside of 6.9%. View Analyst Price Targets for ChemoCentryx.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ChemoCentryx.

Media stories about CCXI stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. ChemoCentryx earned a news impact score of -5.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for ChemoCentryx.

ChemoCentryx saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,460,000 shares, an increase of 21.2% from the January 15th total of 2,030,000 shares. Based on an average daily trading volume, of 1,240,000 shares, the short-interest ratio is presently 2.0 days. Approximately 6.1% of the shares of the company are sold short. View ChemoCentryx's Current Options Chain.

Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer LP Unit (ET), Arrowhead Pharmaceuticals (ARWR), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Amicus Therapeutics (FOLD), Opko Health (OPK), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD) and Amarin (AMRN).

ChemoCentryx's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (15.06%), RA Capital Management L.P. (5.51%), Farallon Capital Management LLC (2.58%), State Street Corp (1.81%), UBS Group AG (1.42%) and Renaissance Technologies LLC (1.32%). Company insiders that own ChemoCentryx stock include Geoffrey M Parker, James L Tyree, Markus J Cappel, Plc Glaxosmithkline, Pui San Kwan, Rajinder Singh, Susan M Kanaya and Thomas J Schall. View Institutional Ownership Trends for ChemoCentryx.

CCXI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Farallon Capital Management LLC, Acadian Asset Management LLC, UBS Group AG, Employees Retirement System of Texas, Bank of America Corp DE, Sei Investments Co. and Barclays PLC. Company insiders that have sold ChemoCentryx company stock in the last year include Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Rajinder Singh, Susan M Kanaya and Thomas J Schall. View Insider Buying and Selling for ChemoCentryx.

CCXI stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., FMR LLC, Lord Abbett & CO. LLC, Sofinnova Investments Inc., State Street Corp, Goldman Sachs Group Inc., Emerald Advisers LLC and Emerald Mutual Fund Advisers Trust. View Insider Buying and Selling for ChemoCentryx.

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CCXI stock can currently be purchased for approximately $48.00.

ChemoCentryx has a market capitalization of $2.79 billion and generates $42.88 million in revenue each year. The biopharmaceutical company earns $-37,970,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. ChemoCentryx employs 76 workers across the globe.View Additional Information About ChemoCentryx.

The official website for ChemoCentryx is http://www.chemocentryx.com/.

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]